Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1139188

registered interest
date	16/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many UK companies have been issued with a licence to sell cannabis products for the NHS.
tabling member constituency	Ross, Skye and Lochaber
tabling member printed	Ian Blackford
uin	277762
answer	answer is ministerial correction date of answer 22/07/2019 answer text <p>Any company meeting the standards for the manufacture of unlicensed medicinal products, can supply cannabis-based products for medicinal use.</p><p>Cannabis-based products for medicinal use are Schedule 2 controlled drugs under the Misuse of Drugs Regulations 2001, which means that manufacturers, importers and distributors of these products must hold valid Home Office and Medicines and Healthcare products Regulatory Agency (MHRA) licences for the relevant activities which will include possession, supply and production of controlled drugs. Where products are sourced from abroad, importers must obtain an import licence from the Home Office and the MHRA each time they import these products.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 22/07/2019 15:41:10 answering member 4455 label Biography information for Seema Kennedy
tabling member	4390 label Biography information for Ian Blackford

1139192

registered interest
date	16/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Eating Disorders: Mental Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that people with eating disorders receive treatment based on their mental state.
tabling member constituency	Peterborough
tabling member printed	Ms Lisa Forbes
uin	277857
answer	answer is ministerial correction date of answer 25/07/2019 answer text <p>All patients should receive necessary treatment appropriate to their individual circumstances.</p><p>National Institute for Health and Care Excellence guidelines suggest that eating disorder specialists and other healthcare teams should collaborate to support effective treatment of physical or mental health comorbidities in people with an eating disorder.</p><p>When collaborating, teams should use outcome measures for both the eating disorder and the physical and mental health comorbidities, to monitor the effectiveness of treatments for each condition and the potential impact they have on each other.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 25/07/2019 10:03:55 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	4717 label Biography information for Ms Lisa Forbes

1139193

registered interest
date	16/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	HIV Infection: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what discussions he is having with the Chancellor of the Exchequer on a long-term and sustainable funding package for the extension of PrEP trials.
tabling member constituency	Dulwich and West Norwood
tabling member printed	Helen Hayes
uin	277792
answer	answer is ministerial correction date of answer 22/07/2019 answer text <p>My Rt. hon. Friend the Secretary of State for Health and Social Care has had numerous discussions with cabinet ministers to discuss a range of topics in advance of the Spending Review. Public health funding for 2020 onwards, including for HIV and sexual health services, will be considered carefully in the next Spending Review, in the light of the available evidence.</p><p>It is for individual local authorities to decide their spending priorities based on an assessment of local need, including sexual health services, taking account of their statutory duties. Participation in the pre-exposure prophylaxis Impact Trial is on a voluntary basis.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 277793 question first answered 22/07/2019 15:40:08 answering member 4455 label Biography information for Seema Kennedy
tabling member	4510 label Biography information for Helen Hayes

1139194

registered interest
date	16/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	HIV Infection: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what discussions he has had with the Chancellor of the Exchequer on a small investment for public health budgets to increase the provision for PrEP trials.
tabling member constituency	Dulwich and West Norwood
tabling member printed	Helen Hayes
uin	277793
answer	answer is ministerial correction date of answer 22/07/2019 answer text <p>My Rt. hon. Friend the Secretary of State for Health and Social Care has had numerous discussions with cabinet ministers to discuss a range of topics in advance of the Spending Review. Public health funding for 2020 onwards, including for HIV and sexual health services, will be considered carefully in the next Spending Review, in the light of the available evidence.</p><p>It is for individual local authorities to decide their spending priorities based on an assessment of local need, including sexual health services, taking account of their statutory duties. Participation in the pre-exposure prophylaxis Impact Trial is on a voluntary basis.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 277792 question first answered 22/07/2019 15:40:08 answering member 4455 label Biography information for Seema Kennedy
tabling member	4510 label Biography information for Helen Hayes

1139199

registered interest
date	16/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Pay
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to paragraph 170 of his Department's Annual Report 2018-19 on the increased NHS resource budget and to the Written Statement on NHS Workforce made on 21 March 2018, HCWS574, if he will clarify when the additional £4.2 billion was agreed by the Chancellor for the NHS Agenda for Change three year pay deal.
tabling member constituency	Leicester South
tabling member printed	Jonathan Ashworth
uin	277749
answer	answer is ministerial correction date of answer 22/07/2019 answer text <p>Funding for the multi-year (2018/19 – 2020/21) Agenda for Change (AfC) pay and contract reform deal was confirmed alongside the Government’s announcement via a Written Ministerial Statement (<a href="https://www.parliament.uk/business/publications/written-questions-answers-statements/written-statement/Commons/2018-06-27/HCWS803/" target="_blank">HCWS803</a>) laid before the House on 27 June 2018 that the Government was accepting the collectively agreed deal. This statement followed the previous Written Ministerial Statement (<a href="https://www.parliament.uk/business/publications/written-questions-answers-statements/written-statement/Commons/2018-03-21/HCWS574/" target="_blank">HCWS574</a>) laid before the house on 21 March 2018 in which additional funding for the AfC deal was committed to should trades union members agree to the deal.</p><p>In line with the Chancellor’s commitment at Budget 2017, the Government released the £800 million already set aside to support the first year of the deal for 2018/19 in England.</p><p>Funding for the remaining two years of the deal (2019/20 and 2020/21) has been made available as part of the long-term funding settlement for the National Health Service.</p><p> </p><p> </p><p><strong> </strong></p><p><strong> </strong></p> answering member constituency Wimbledon answering member printed Stephen Hammond question first answered 22/07/2019 15:33:16 answering member 1585 label Biography information for Stephen Hammond
tabling member	4244 label Biography information for Jonathan Ashworth

1139213

registered interest
date	16/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer: County Durham
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps is he taking to reduce the number of emergency cancer diagnoses in County Durham.
tabling member constituency	Easington
tabling member printed	Grahame Morris
uin	277701
answer	answer is ministerial correction date of answer 22/07/2019 answer text <p>Improving diagnosis and ensuring better outcomes for patients diagnosed with cancer is a priority for the Durham Dales, Easington and Sedgefield Clinical Commissioning Group (CCG). To achieve this, the CCG is working collaboratively with colleagues from public health, primary care and secondary care on a strategic piece of work. The CCG believes that a multi-disciplinary approach is necessary in order to address inequalities.</p><p> </p><p><strong> </strong></p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 22/07/2019 14:26:20 answering member 4455 label Biography information for Seema Kennedy
tabling member	3973 label Biography information for Grahame Morris

1139214

registered interest
date	16/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will commission a fully-funded long-term cancer workforce plan for the NHS to help ensure increased patient demand is met.
tabling member constituency	Easington
tabling member printed	Grahame Morris
uin	277702
answer	answer is ministerial correction date of answer 22/07/2019 answer text <p>The interim NHS People Plan, published on 3 June 2019, puts the workforce at the heart of the National Health Service and will ensure we have the staff needed to deliver high quality care. A final People Plan will be published soon after the conclusion of the 2019 Spending Review.</p><p>Phase 1 of the Cancer Workforce Plan for England, published in December 2017 by Health Education England (HEE), set out plans to expand capacity and skills in the cancer workforce, including targeting additional training support for seven priority professions which are key to cancer prevention, diagnosis and treatment, such as clinical radiology, histopathology, oncology and diagnostic and therapeutic radiography.</p><p>HEE will now work with NHS England and NHS Improvement to understand the longer-term workforce implications of further development of cancer services. This work will inform the final People Plan.</p><p> </p><p><strong> </strong></p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 22/07/2019 14:31:02 answering member 4455 label Biography information for Seema Kennedy
tabling member	3973 label Biography information for Grahame Morris

1139217

registered interest
date	16/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Clinical Commissioning Groups: Finance
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure funding for Clinical Commissioning Groups is equitable and protects patient outcomes.
tabling member constituency	Peterborough
tabling member printed	Ms Lisa Forbes
uin	277858
answer	answer is ministerial correction date of answer 22/07/2019 answer text <p>The allocation of funding to clinical commissioning groups (CCGs) to support them in commissioning services for their local population is one of the key duties of NHS England. The approach NHS England must take in setting allocations is outlined in the mandate from the Department which says:</p><p><em> </em></p><p>“The Government expects the principle of ensuring equal access for equal need to be at the heart of NHS England’s approach to allocating budgets.”</p><p> </p><p>The approach is also informed by NHS England’s duty to reduce inequalities to accessing services and the outcomes of care.</p><p> </p><p>These two aims are reflected in the target formula, which produces a target allocation or ‘fair share’ for each area, based on a complex assessment of factors such as demography, morbidity, deprivation, and the unavoidable cost of providing services in different areas. The NHS England Board has agreed a pace of change policy that seeks to bring all CCGs to target funding over time.</p><p> </p><p>The formula is based on independent academic research and is overseen by an independent external group, the Advisory Committee on Resource Allocation, which provides advice to the Secretary of State for Health and Social Care and the Chief Executive of NHS England.</p><p><strong> </strong></p> answering member constituency Wimbledon answering member printed Stephen Hammond question first answered 22/07/2019 15:41:44 answering member 1585 label Biography information for Stephen Hammond
tabling member	4717 label Biography information for Ms Lisa Forbes

1139219

registered interest
date	16/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medical Equipment: UK Notified Bodies
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what recent representations he has received from the medical technology sector on the capacity of Notified Bodies to meet the demand for their services under the provisions of the Medical Devices Regulation; and if he will make a statement.
tabling member constituency	Bolton West
tabling member printed	Chris Green
uin	277763
answer	answer is ministerial correction date of answer 25/07/2019 answer text <p>New European Union Regulations for medical devices (MDR) entered into force in May 2017 and will fully apply from May 2020.</p><p>The new Regulations substantially strengthen the regulatory framework for medical devices and notified bodies are having to make significant changes to meet the enhanced requirements. These changes have the aim of improving the quality, consistency and rigour of notified body assessments, which was one of the Government’s key aims for the new legislation.</p><p>Ministers have met with and received letters from industry representatives who have raised concerns about capacity in the notified body sector across the EU to support the implementation of the MDR. The Government recognises the importance of having competent notified bodies across the EU in place in sufficient time to ensure continuity of supply of products to the United Kingdom market.</p><p>For this reason, at the Employment, Social Policy, Health and Consumer Affairs (EPSCO) Council on 14 June, the Parliamentary Under-Secretary of State (Baroness Blackwood of North Oxford) raised the Government’s concerns about the readiness of critical infrastructure required to implement the MDR and the risk that some existing and new to market products will not be available to patients as a result.</p><p>We very much recognise the benefits of the new Regulations and the imperative of full implementation as soon as possible in the interests of patient safety. Therefore, at EPSCO the Government emphasised the importance of finding a coordinated solution at an EU level and we will continue to do what we can to influence these discussions.</p><p>In parallel with this activity, the Medicines and Healthcare products Regulatory Agency (MHRA) has been engaging with its notified bodies on an ongoing basis to ensure that sufficient resources are in place and notified bodies are prepared for the implementation of the new EU legislation. The MHRA is also offering a substantial amount of resource to the EU in order to support and expedite the designation process.</p><p>Through the Office for Life Sciences, the Government plans to work with stakeholders to come to a shared understanding of the issues and discuss what further mitigating action could be taken. Further engagement with industry will therefore take place in the short term.</p><p> </p> answering member constituency Thurrock answering member printed Jackie Doyle-Price grouped question UIN 277764 278523 question first answered 25/07/2019 10:00:04 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	4398 label Biography information for Chris Green

1139220

registered interest
date	16/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medical Devices (Amendment etc.) (EU Exit) Regulations 2019
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether he plans to seek an extension to the implementation period of the Medical Devices Regulation from the EU.
tabling member constituency	Bolton West
tabling member printed	Chris Green
uin	277764
answer	answer is ministerial correction date of answer 25/07/2019 answer text <p>New European Union Regulations for medical devices (MDR) entered into force in May 2017 and will fully apply from May 2020.</p><p>The new Regulations substantially strengthen the regulatory framework for medical devices and notified bodies are having to make significant changes to meet the enhanced requirements. These changes have the aim of improving the quality, consistency and rigour of notified body assessments, which was one of the Government’s key aims for the new legislation.</p><p>Ministers have met with and received letters from industry representatives who have raised concerns about capacity in the notified body sector across the EU to support the implementation of the MDR. The Government recognises the importance of having competent notified bodies across the EU in place in sufficient time to ensure continuity of supply of products to the United Kingdom market.</p><p>For this reason, at the Employment, Social Policy, Health and Consumer Affairs (EPSCO) Council on 14 June, the Parliamentary Under-Secretary of State (Baroness Blackwood of North Oxford) raised the Government’s concerns about the readiness of critical infrastructure required to implement the MDR and the risk that some existing and new to market products will not be available to patients as a result.</p><p>We very much recognise the benefits of the new Regulations and the imperative of full implementation as soon as possible in the interests of patient safety. Therefore, at EPSCO the Government emphasised the importance of finding a coordinated solution at an EU level and we will continue to do what we can to influence these discussions.</p><p>In parallel with this activity, the Medicines and Healthcare products Regulatory Agency (MHRA) has been engaging with its notified bodies on an ongoing basis to ensure that sufficient resources are in place and notified bodies are prepared for the implementation of the new EU legislation. The MHRA is also offering a substantial amount of resource to the EU in order to support and expedite the designation process.</p><p>Through the Office for Life Sciences, the Government plans to work with stakeholders to come to a shared understanding of the issues and discuss what further mitigating action could be taken. Further engagement with industry will therefore take place in the short term.</p><p> </p> answering member constituency Thurrock answering member printed Jackie Doyle-Price grouped question UIN 277763 278523 question first answered 25/07/2019 10:00:04 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	4398 label Biography information for Chris Green